We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy (OPTILIV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00852228
Recruitment Status : Unknown
Verified December 2013 by Association pour la Recherche sur le Temps Biologique et la Chronothérapie.
Recruitment status was:  Active, not recruiting
First Posted : February 26, 2009
Last Update Posted : December 12, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
The primary objective of the study is to increase by 15% the complete macroscopic resection rate of predominantly liver metastases from metastatic colorectal cancer through combining systemic cetuximab and hepatic artery infusion of three-drug chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil).

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Liver Metastases Hepatic Lesions Drug: IV cetuximab Drug: HAI chronomodulated chemotherapy Drug: HAI conventional chemotherapy Phase 2

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial
Study Start Date : July 2008
Primary Completion Date : March 2012
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: chronomodulated HAI chemotherapy Drug: IV cetuximab
Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
Other Name: Erbitux
Drug: HAI chronomodulated chemotherapy

Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00

Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.

5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.

Treatments will be repeated every 2 weeks.

Other Names:
  • Campto
  • Eloxatin
Experimental: conventional HAI chemotherapy Drug: IV cetuximab
Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
Other Name: Erbitux
Drug: HAI conventional chemotherapy

Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then

Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then

5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.

Treatments will be repeated every 2 weeks.

Other Names:
  • Campto
  • Eloxatin

Outcome Measures

Primary Outcome Measures :
  1. Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy. [ Time Frame: evaluation every 6th week up to 18 weeks ]

Secondary Outcome Measures :
  1. The rate and site(s) of relapse in the resected patients throughout the 3-year span that follows hepatectomy [ Time Frame: every 2 month up to 3 years ]
  2. The relapse-free survival in the resected patients [ Time Frame: every 2nd month up to 3 years ]
  3. The progression-free and the overall survival in the patients receiving at least 4 full courses of HAI therapy and in all the patients (intent to treat) [ Time Frame: every 2nd month up to 3 years ]
  4. The objective response rate [ Time Frame: every 6 weeks up to 18 weeks ]
  5. The rate of adverse events [ Time Frame: continuous up to 30 days following end of treatment ]
  6. The per-operative and post-operative complications associated to liver surgery [ Time Frame: continuous up to 3 months following surgery ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of liver metastases (new confirmation of metastatic disease is required in case the time interval from last histological diagnosis to enrolment exceeds 3 years).
  • Patient with wild type (WT) KRAS tumor status
  • Patient whose liver metastases are considered to be non resectable with curative intent in medico-surgical staff meeting. In particular patients with at least one of the following criteria, which prevent complete local treatment of liver metastasis with surgery alone or surgery plus radiofrequency ablation because:

    • less than 30% estimated residual liver after resection
    • disease in contact with liver main vessels
    • documented progressive disease on imaging documents or doubling of serum levels of carcino-embryonic antigen (CEA) or CA19.9 over the past 90 days or less
  • Patient with up to three resectable extrahepatic nodules of <= 10 mm
  • One, two or three prior chemotherapy lines for colorectal cancer.
  • Written informed consent.
  • Age >=18 years.
  • Patient must be able to comply with the protocol.
  • Life expectancy of at least 3 months.
  • At least one measurable metastatic liver lesion (as per RECIST criteria).
  • World Health Organization performance status of 0 or 1.
  • Adequate hematological function: absolute neutrophil count (ANC) >=1.0 x 10^9/L; platelets >=75 x 10^9/L, hemoglobin (Hb) >=8.5 g/dL.
  • International normalized ratio (INR) <=1.5 and activated partial thromboplastin time (aPTT) <=1.5 x upper limit of normal (ULN) within 7 days prior to starting study treatment, in the absence of anticoagulant therapy.
  • Liver function: serum bilirubin <=1.5 x ULN; alkaline phosphatase and transaminases <5 x ULN (liver metastases).
  • Serum creatinine <= 1.5 x ULN.
  • Fertile women and men of childbearing potential (<2 years after last menstruation in women) must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile).

Exclusion Criteria:

  • Patient whose primary tumor or metastasis displays mutation of K-Ras (codon 12 and/or 13).
  • Unresectable extrahepatic diseases.
  • More than three resectable extrahepatic nodules.
  • Size of extra hepatic nodules > 1 cm
  • Prior HAI of the 3 drugs.
  • More than 2 prior surgical attempts for metastatic disease
  • Prior radiotherapy for metastatic disease
  • Known documented intolerance or hypersensitivity to any of the drugs used.
  • Sensory neuropathy grade 3 (National Cancer Institute-Common Terminology Criteria for Adverse Events -NCI-CTCAE, Version 3.0).
  • Past or current history (within the last 2 years prior to treatment start) of malignancy other than colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible).
  • Serious, non healing wound, ulcer, or bone fracture.
  • Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that puts the patient at high risk for treatment-related complications.
  • Pregnancy or lactation
  • Fertile women (< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.

Prior systemic administration of cetuximab or other anti-EGFR agent is not an exclusion criterion.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00852228

Clinique Saint-Joseph
Liège, Belgium, 4000
CHU de Bordeaux, Hôpital Saint-André
Bordeaux, France, 33000
Hôpital Ambroise Paré
Boulogne-Billancourt, France, 92100
Centre Jean Perrin
Clermont-Ferrand, France, 63011
CHRU de Lille, Hôpital Claude Huriez
Lille, France, 59037
Hôpital Cochin
Paris, France, 75014
Hôpital Européen Georges Pompidou
Paris, France, 75015
CHU Toulouse
Toulouse, France, 31059
Chronotherapy Unit, Medical Oncology Department, Paul Brousse Hospital
Villejuif, France, 94800
Institut Gustave Roussy
Villejuif, France, 94800
Università G. d'Annunzio
Chieti, Italy, 66100
Azienda Ospedaliera S.Maria Degli Angeli
Pordenone, Italy, 33170
Istituto Regina Elena
Roma, Italy, 00144
Hospital Fernando Fonesca
Amadora, Portugal, 27000
Sponsors and Collaborators
Association pour la Recherche sur le Temps Biologique et la Chronothérapie
Gustave Roussy, Cancer Campus, Grand Paris
Merck Serono International SA
Principal Investigator: Francis A. Lévi, M.D., Ph.D. Paul Brousse Hospital, Villejuif, France
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Association pour la Recherche sur le Temps Biologique et la Chronothérapie
ClinicalTrials.gov Identifier: NCT00852228     History of Changes
Other Study ID Numbers: OPTILIV07
EUDRACT number: 2007-004632-24
First Posted: February 26, 2009    Key Record Dates
Last Update Posted: December 12, 2013
Last Verified: December 2013

Keywords provided by Association pour la Recherche sur le Temps Biologique et la Chronothérapie:
colorectal cancer
unresectable metastases
neo-adjuvant chemotherapy
liver metastases
hepatic artery infusion
Unresectable hepatic lesions
1 to 3 prior chemotherapy regimens

Additional relevant MeSH terms:
Colorectal Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Liver Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents